Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults

• Status: Completed
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a combination of a radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and CCNU) in adult patients with medulloblastoma is tolerable.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Regensburg
• Treatments: Cisplatin; Lomustine; Vincristine

Criteria

Inclusion Criteria:

• age > 18 years

• medulloblastoma (+/- postoperative residual tumor, M0) or medulloblastoma (+/- postoperative residual tumor, M1-M3) respectively

• primary diagnosis of the tumor

• no previous chemo- or radiation therapy

• Karnofsky-Index ≥ 70%

• WBC ≥ 3000/μl; thrombocytes ≥ 100 000/μl; Hb ≥ 10 g/dl

• creatinine =< 1,5 ULN; Bilirubin =< 1,5 ULN; GPT, GOT, AP =< 2,5 ULN

• HIV and hepatitis B/C negative

• no factors / any medical condition affecting patient's compliance

• patient needs to fulfil protocol's requirements

• patient is willing to use highly effective methods of contraception during dosing and for 6 months after the last dose; women of child-bearing potential must have a negative hCG laboratory test at baseline; pregnancy tests must be repeated every 4 weeks

• patient's written consent

Exclusion Criteria:

• age < 18 years

• histologically not confirmed Medulloblastoma

• by chemo- or radiotherapy treated recidive tumor

• other cancer (with exception of surgically cured carcinoma in situ of the cervix and non-melanocytic skin tumors)

• hypersensitivity or contraindication against one of the used drugs

• current or planned participation to another clinical trial during this study Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrolment or could interfere with the patient participating in and completing the study

• Any medical condition associated with high medical risk or contraindicated to use chemotherapeutic agents as indicated in current product package insert

• Pregnant or nursing (lactating) women; women or men not willing to use a highly effective methods of contraception